NDC 69097-361

grisofulvin

Grisofulvin

grisofulvin is a Oral Suspension in the Human Prescription Drug category. It is labeled and distributed by Cipla Usa Inc.. The primary component is Griseofulvin.

Product ID69097-361_883762d6-5d17-4ccd-99e6-254a6ad208ef
NDC69097-361
Product TypeHuman Prescription Drug
Proprietary Namegrisofulvin
Generic NameGrisofulvin
Dosage FormSuspension
Route of AdministrationORAL
Marketing Start Date2017-03-06
Marketing CategoryANDA / ANDA
Application NumberANDA065354
Labeler NameCipla USA Inc.
Substance NameGRISEOFULVIN
Active Ingredient Strength125 mg/5mL
Pharm ClassesDecreased Mitosis [PE],Microtubule Inhibition [PE],Tubulin Inhibiting Agent [EPC]
NDC Exclude FlagN
Listing Certified Through2020-12-31

Packaging

NDC 69097-361-08

120 mL in 1 BOTTLE (69097-361-08)
Marketing Start Date2017-03-06
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 69097-361-08 [69097036108]

grisofulvin SUSPENSION
Marketing CategoryANDA
Application NumberANDA065354
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitML
Marketing Start Date2017-03-06

Drug Details

Active Ingredients

IngredientStrength
GRISEOFULVIN125 mg/5mL

OpenFDA Data

SPL SET ID:d5c737e5-51b8-4322-a2a5-4d4a392c1f56
Manufacturer
UNII
RxNorm Concept Unique ID - RxCUI
  • 239238
  • UPC Code
  • 0369097361082
  • Pharmacological Class

    • Decreased Mitosis [PE]
    • Microtubule Inhibition [PE]
    • Tubulin Inhibiting Agent [EPC]
    • Decreased Mitosis [PE]
    • Microtubule Inhibition [PE]
    • Tubulin Inhibiting Agent [EPC]

    Medicade Reported Pricing

    69097036108 GRISEOFULVIN 125 MG/5 ML SUSP

    Pricing Unit: ML | Drug Type:

    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.